Piramal Pharma Limited has submitted a regulatory disclosure to BSE Limited and National Stock Exchange of India Limited intimating a conference call with investors and analysts. The disclosure is made pursuant to Regulation 30(6) of the SEBI Listing Regulations.
The company will host an earnings conference call to discuss its Q1 FY2027 results on 30th July 2026 from 9:30 AM to 10:15 AM IST.
Conference Call Details
Date: 30th July 2026
Time: 9:30 AM to 10:15 AM IST
Purpose: Discussion of Q1 FY2027 Results
Dial-in Information:
- India: +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) | Toll free: 1 800 120 1221
- USA: 12:00 AM Eastern Time (New York) | Toll free: 18667462133
- UK: 05:00 AM London Time | Toll free: 08081011573
- Singapore: 12:00 PM Singapore Time | Toll free: 8001012045
- Hong Kong: 12:00 PM Hong Kong Time | Toll free: 800964448
Participants can use Express Join with Diamond Pass™ through a provided link for prior registration to reduce wait time.
Company Background
Piramal Pharma Limited operates with 17 global development and manufacturing facilities and a distribution network in over 100 countries. The company's business segments include:
- Piramal Pharma Solutions (PPS): Integrated contract development and manufacturing organization
- Piramal Critical Care (PCC): Complex hospital generics business
- Piramal Consumer Healthcare: Over-the-counter consumer and wellness products
The company has an associate company, Abbvie Therapeutics India Private Limited (a joint venture with Abbvie), which is a market leader in ophthalmology therapy in India. PPL also holds a strategic minority investment in Yapan Bio Private Limited, which operates in biologics/bio-therapeutics and vaccine segments.